Clinical trials: Cetuximab
Metastatic Colorectal Cancer
Comparing Efficacy and Safety of Cetuximab (CinnaGen) Versus Erbitux® (Merck) in Metastatic Colorectal Cancer
The study is designed as phase III, randomized, two armed, parallel, double blind (patient and assessor blinded), active controlled, and equivalency clinical trial with primary endpoint of Progression-Free Survival of Cetuximab®…
- Trial name
- NCT03391934
- Testing
- Cetuximab + FOLFIRI
- Where
- Iran
- Volunteers
- 234 people
- Sponsor
- Cinnagen
Head and Neck Squamous Cell Carcinoma
Platinum-Cetuximab Combined With Docetaxel or With 5FU in Patients With Recurrent/Metastatic HNSCC
This study evaluates the efficacy of the new docetaxel-cisplatin-cetuximab regimen (TPEx) versus the standard platinum-5FU-cetuximab EXTREME regimen as a first-line treatment in recurrent and/or metastatic HNSCC.
- Trial name
- TPExtreme (NCT02268695)
- Testing
- Cisplatin, 5-Fluorouracile, Docetaxel
- Where
- 17 sites in France, Germany and 1 more
- Volunteers
- 541 people
- Sponsor
- Groupe Oncologie Radiotherapie Tete et Cou
Colorectal Cancer
Cetuximab & Celecoxib for Metastatic Colorectal Cancer or Colorectal Cancer That Cannot Be Removed by Surgery
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00466505
- Testing
- cetuximab, celecoxib, proteomic profiling
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Colon Cancer, Breast Cancer, Cancer of the Head and Neck
Safety, Immunogenicity and Pharmacokinetics of SYN004 in Patients With Solid Tumors
A first-in-human evaluation of SYN004, a monoclonal antibody that binds to the EGF receptor on cancer cells. Cetuximab, a marketed antibody, has been shown to be effective by inhibiting the growth of cancer cells thereby…
- Trial name
- SYN004_Ph_1 (NCT02391727)
- Testing
- SYN004
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Synermore Biologics Co., Ltd.
Colorectal Cancer
FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal Cancer
The goal of the Phase I part of this clinical research study is to find the highest tolerable dose of a combination of dasatinib, cetuximab, and FOLFOX (5-fluorouracil [5-FU], leucovorin [LV], and Eloxatin [oxaliplatin]) that can…
- Trial name
- NCT00501410
- Testing
- 5-FU, Cetuximab, Dasatinib
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- M.D. Anderson Cancer Center
Treatment Related Cancer
FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC
Within the proposed single arm multicenter phase-II trial it is intended to investigate the feasi-bility of adding Avelumab to FOLFIRI plus Cetuximab after 4 cycles (2 months) of treatment with FOLFIRI plus Cetuximab.
- Trial name
- NCT05217069
- Testing
- 5-FU, Folinic Acid, Irinotecan
- Where
- Germany
- Volunteers
- 57 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Colorectal Cancer
Cetuximab and Savolitinib Treatment of Ras Wild-Type Colorectal Cancer
Two-part phase 1B clinical trial combining cextuximab and savolitinib for treating Ras wild-type colorectal cancer (CRC). Part 1 will assess the safety and tolerability of this drug combination and will include patients with…
- Trial name
- NCT02630420
- Testing
- cetuximab and savolitinib
- Sponsor
- Yale University
Pancreatic Cancer
Gemcitabine/Cisplatin +/-Cetuximab in Patients With Locally Advanced or Metastatic EGFR-Positive Pancreatic Cancer
This is multicenter, open-label, randomized, phase II trial in patients with locally advanced or metastatic pancreatic cancer. Primary objective: objective response rate.
- Trial name
- SPaCe-01 (NCT00536614)
- Testing
- cetuximab
- Where
- 10 sites in Italy
- Volunteers
- 86 people
- Sponsor
- Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma
The purpose of this research study is to look at the effect of a treatment regimen called CACTUX on head and neck cancer. The CACTUX regimen is a combination of three drugs called cisplatin, nab-paclitaxel, and cetuximab…
- Conditions
- Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Cancer of the Head and Neck
- Trial name
- CACTUX (NCT02270814)
- Testing
- nab-paclitaxel, Cisplatin, Carboplatin
- Where
- 5 sites in United States
- Volunteers
- 74 people
- Sponsor
- Washington University School of Medicine
Colorectal Cancer, Liver Metastases
Conversion Therapy of RAS/BRAF Wild-Type Right-sided Colon Cancer Patients With Initially Unresectable Liver Metastases
The prognosis of patients with metastatic right-sided colon cancer is worse than that of patients with metastatic left-sided cancer.
- Trial name
- NCT04525326
- Testing
- Cetuximab, Bevacizumab, mFOLFOX/FOLFIRI ( Standard Chemotherapy)
- Volunteers
- 584 people
- Sponsor
- Fudan University
Colorectal Cancer
PETACC-8 miR-31-3p and miR-31-5p Ancillary Study
This is a prospective-retrospective study to determine if the expression of the miRNA's miR-31-3p and miR-31-5p are prognostic of patient outcomes or predictive of the benefit from anti-EGFR therapy in stage III Colon Cancer.
- Trial name
- NCT03362684
- Testing
- Cetuximab, FOLFOX
- Volunteers
- 1,808 people
- Sponsor
- IntegraGen SA
Colon Adenocarcinoma, Rectal Adenocarcinoma
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
Researchers are looking for other ways to treat locally advanced or metastatic colorectal cancer (mCRC) that is unresectable and has a gene mutation called KRAS G12C.
- Trial name
- NCT06997497
- Testing
- Calderasib, Oxaliplatin, Leucovorin/levofolinate calcium
- Where
- 244 sites in United States, Argentina and 27 more
- Volunteers
- 477 people
- Sponsor
- Merck Sharp & Dohme LLC
Head and Neck Cancer
Cetuximab, Carboplatin, and Paclitaxel Followed by Radiation Therapy, With or Without Cisplatin, in Treating Patients With Metastatic Head and Neck Cancer
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some find tumor cells and kill them or carry tumor-killing substances to them.
- Trial name
- NCT00301028
- Testing
- Cetuximab, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- M.D. Anderson Cancer Center
Colorectal Neoplasms
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
This study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer.
- Trial name
- MOUNTAINEER-03 (NCT05253651)
- Testing
- tucatinib, trastuzumab, bevacizumab
- Where
- 366 sites in United States, Argentina and 23 more
- Volunteers
- 400 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Head and Neck Neoplasms
Durvalumab, Cetuximab and Radiotherapy in Head Neck Cancer
In over 60% of cases, squamous cell carcinoma of the head and neck (SCCHN) is discovered at a loco-regionally advanced stage that requires a combined multimodal strategy in order to pursue a curative intent.
- Trial name
- DUCRO-HN (NCT03051906)
- Testing
- Durvalumab, Cetuximab, Intensity modulated radiation therapy (IMRT)
- Volunteers
- 69 people
- Sponsor
- Azienda Ospedaliero-Universitaria Careggi
Metastatic Colorectal Cancer, Non-Small-Cell Lung Carcinoma
Study About Preventive Treatment of Folliculitis Induced by Epidermal Growth Factor Receptor Inhibitors
Patients will receive local prophylactic treatment (Diprosone cream) during 8 weeks from the beginning of the EGF-R inhibitors treatment, on the areas of the body susceptible to be affected by folliculitis.
- Trial name
- DIPROCOL (NCT00910676)
- Testing
- Diprosone
- Where
- 3 sites in France
- Volunteers
- 30 people
- Sponsor
- Centre Oscar Lambret
Colorectal Cancer
Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer
This study will assess the safety and efficacy of LGX818 when combined with cetuximab or combined with cetuximab and BYL719 in patients with BRAF mutant metastatic colorectal cancer
- Trial name
- NCT01719380
- Testing
- LGX818, Cetuximab, BYL719
- Where
- 52 sites in United States, Australia and 10 more
- Volunteers
- 156 people
- Sponsor
- Pfizer
Colon Cancer, Resected Stage
A PHASE IB STUDY OF IMMUNOTHERAPY WITH EX VIVO PRE-ACTIVATED AND EXPANDED CB-NK CELLS IN COMBINATION WITH CETUXIMAB, IN COLORECTAL CANCER PATIENTS WITH MINIMAL RESIDUAL DISEASE (MRD)
A study of immunotherapy with expanded CB-NK cells in combination with cetuximab, to evaluate activity against minimal residual disease in patients with colon cancer that have completed adjuvant treatment but are positive for…
- Trial name
- NCT05040568
- Testing
- Cetuximab, Expanded CB-NK cells, Fludarabine phosphate
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Head and Neck Cancer
Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
The main purpose of this study is to compare nivolumab and ipilimumab with the extreme regimen as first line treatment in patients with recurrent or metastatic squamous cell of the head and neck cancer
- Trial name
- CheckMate 651 (NCT02741570)
- Testing
- Nivolumab, Ipilimumab, Cetuximab/Erbitux
- Where
- 133 sites in United States, Australia and 16 more
- Volunteers
- 947 people
- Sponsor
- Bristol-Myers Squibb
Cervical Squamous Cell Carcinoma, Recurrent Cervical Carcinoma
Cetuximab in Treating Patients With Persistent or Recurrent Cervical Cancer
This phase II trial is studying cetuximab to see how well it works in treating patients with persistent or recurrent cervical cancer. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways.
- Trial name
- NCT00499031
- Testing
- Cetuximab
- Where
- 22 sites in United States
- Volunteers
- 38 people
- Sponsor
- Gynecologic Oncology Group